Andrea Lobo,  —

The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis (MG). The designation is given to medicines that aim to treat life-threatening or chronic debilitating conditions affecting no more than five in every 10,000 people. It provides companies with several…

Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized myasthenia gravis with anti-AChR antibodies, a real-world study in Italy shows. The treatment also reduced the number of disease exacerbations that required rescue therapy, such as intravenous immunoglobulin (IVIG)…

Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to require intensive care due to disease exacerbation, a retrospective study in Finland suggests. Patients with late-onset disease in whom disease symptoms become apparent after the age of 50 were also…

The new UCB Myasthenia Gravis Scholarship, launched by the Belgium-based biopharmaceutical company, is aiming to help myasthenia gravis (MG) patients and their family members in the U.S. to continue their education or learn new skills by covering educational expenses — with program awards totaling up to $150,000. “We…

Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number of cases and the number of newly diagnosed cases both rising, according to a population-based study. The number of newly diagnosed cases was higher among men older than 50 and…

The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following chemoimmunotherapy for gastric cancer that included sintilimab showcases the need to better understand how this treatment can induce the immune disorder, said researchers in China. Sintilimab is a type of…

Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated…

Johnson & Johnson has submitted an application to the European Medicines Agency (EMA) seeking approval of nipocalimab to treat people with generalized myasthenia gravis (gMG). The request includes gMG patients who are positive for MG-causing autoantibodies targeting acetylcholine receptors (AChRs), muscle-specific tyrosine (MuSK), and low-density lipoprotein…

Surgical removal of the thymus, called a thymectomy, may significantly ease the neurological symptoms of patients older than 65 who have myasthenia gravis (MG) and a thymus tumor, according to a new study from researchers in Italy. Overall, nearly 90% of older individuals undergoing thymectomy showed a neurological…

UCB’s injection therapy Zilbrysq (zilucoplan) has gained approval in Canada for treating adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). The decision by Health Canada was supported by results from the Phase 3 RAISE trial (NCT04115293), in which the…